Tocilizumab
- Is there a potential for therapeutic drug monitoring of subcutaneously administered tocilizumab in patients with rheumatoid arthritis in daily practice? Layegh et al., Clin Exp Rheumatol. 2022 Mar;40(3):664-665. doi: 10.55563/clinexprheumatol/xn5i2y. Epub 2021 Nov 3. PMID: 34796848.
- Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study. Moes et al., Clin Pharmacokinet. 2022 Feb;61(2):231-247. doi: 10.1007/s40262-021-01074-2. Epub 2021 Oct 11. PMID: 34633645; PMCID: PMC8502793.
- Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations. Bastida et al., Eur J Clin Pharmacol. 2020 Oct;76(10):1417-1425. doi: 10.1007/s00228-020-02925-w. Epub 2020 Jun 9. PMID: 32514745.
- Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study. Kneepkens et al., Scand J Rheumatol. 2017 Mar;46(2):87-94.
